Package Leaflet: Information for the User
HBVAXPRO 10 micrograms, suspension for injection
Hepatitis B vaccine (rDNA)
Read all of this leaflet carefully before you are vaccinated because it contains important information for you.
Contents of the pack
This vaccine is indicated for active immunization against hepatitis B virus infection caused by all known subtypes, in individuals from 16 years of age considered at risk of exposure to hepatitis B virus.
It can be expected that immunization with HBVAXPRO will also prevent hepatitis D, since hepatitis D does not occur in the absence of hepatitis B infection.
The vaccine does not prevent infections caused by other agents such as hepatitis A, hepatitis C, and hepatitis E, or by other pathogens known to infect the liver.
Do not use HBVAXPRO 10 micrograms
Warnings and precautions
It can cause severe allergic reactions because it contains latex in the packaging. Consult your doctor, pharmacist or nurse before receiving HBVAXPRO 10 micrograms.
Other vaccines and HBVAXPRO 10 micrograms
HBVAXPRO can be given at the same time as hepatitis B immunoglobulin, in different injection sites.
HBVAXPRO can be used to complete a primary immunization cycle or as a booster dose in individuals who have previously received another hepatitis B vaccine.
HBVAXPRO can be given at the same time as other vaccines, using different injection sites and syringes.
Tell your doctor, pharmacist or nurse if you are taking or have recently taken any other medicines, including those obtained without a prescription.
Pregnancy and lactation
Caution should be exercised when prescribing the vaccine to pregnant or breastfeeding women.
Consult your doctor, pharmacist or nurse before using any medicine.
Driving and using machines
HBVAXPRO is not expected to have a significant effect on the ability to drive and use machines.
HBVAXPRO 10 micrograms contains sodium: this medicine contains less than 23 mg of sodium (1 mmol) per dose; it is essentially "sodium-free".
Dose
The recommended dose per injection (1 ml) is 10 micrograms in individuals from 16 years of age.
A vaccination cycle should include at least three injections.
Two vaccination schedules can be recommended:
In the event of recent exposure to hepatitis B virus, the first dose of HBVAXPRO can be given along with the appropriate dose of immunoglobulin.
Some local vaccination schedules currently recommend a booster dose. Your doctor, pharmacist or nurse will inform you if you need a booster dose.
HBVAXPRO 10 micrograms is not indicated in individuals under 16 years of age.
The appropriate dose for administration to individuals from birth to 15 years of age is HBVAXPRO 5 micrograms.
Method of administration
The vial should be shaken well until a slightly opaque white suspension is obtained. The doctor or nurse will administer the vaccine by injection into the muscle. The preferred injection site in adults and adolescents is the muscle of the upper arm.
This vaccine should never be administered into a blood vessel.
Exceptionally, the vaccine can be administered subcutaneously in patients with thrombocytopenia (decreased blood platelets) or in individuals at risk of bleeding.
If you miss a dose of HBVAXPRO 10 micrograms
If you miss a scheduled injection, consult your doctor, pharmacist or nurse. Your doctor or nurse will decide when to administer the missed dose.
If you have any further questions about the use of this product, consult your doctor, pharmacist or nurse.
Like all medicines, this vaccine can cause side effects, although not everybody gets them.
As with other hepatitis B vaccines, in many cases, a causal relationship between the side effects and the vaccine has not been established.
The most frequently observed side effects are reactions at the injection site: discomfort, redness, and induration.
Other side effects reported very rarely are:
Reporting of side effects
If you experience any side effects, talk to your doctor, pharmacist or nurse, even if they are not listed in this leaflet. You can also report side effects directly through the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this vaccine out of the sight and reach of children.
Do not use this vaccine after the expiry date which is stated on the label.
Store in a refrigerator (between 2°C and 8°C).
Do not freeze.
Store in the original packaging to protect from light.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
Composition of HBVAXPRO 10 micrograms
The active substance is:
Recombinant hepatitis B surface antigen (HBsAg)*……..10 micrograms
Adsorbed on amorphous aluminum hydroxyphosphate sulfate (0.50 milligrams Al+)
The adjuvant is included in this vaccine to accelerate, enhance, and/or prolong the protective effects of the vaccine.
The other ingredients are sodium chloride (NaCl), sodium borate, and water for injections.
Appearance and packaging of HBVAXPRO 10 micrograms
HBVAXPRO 10 micrograms is a suspension for injection in a vial. Pack sizes of 1 and 10 vials.
Not all pack sizes may be marketed.
Marketing Authorisation Holder and Manufacturer
Merck Sharp & Dohme B.V., Waarderweg 39, 2031 BN Haarlem, Netherlands
For further information about this vaccine, please contact the local representative of the Marketing Authorisation Holder.
België/Belgique/Belgien MSD Belgium Tél/Tel: +32(0)27766211 dpoc_belux@merck.com | Lietuva UAB Merck Sharp & Dohme Tel.: +370.5.2780.247 msd_lietuva@merck.com |
info-msdbg@merck.com | Luxembourg/Luxemburg MSD Belgium Tél/Tel: +32(0)27766211 dpoc_belux@merck.com |
Ceská republika Merck Sharp & Dohme s.r.o. Tel.: +420 233 010 111 dpoc_czechslovak@merck.com | Magyarország MSD Pharma Hungary Kft. Tel.: + 36.1.888.5300 hungary_msd@merck.com |
Danmark MSD Danmark ApS Tlf: + 45 4482 4000 dkmail@merck.com | Malta Merck Sharp & Dohme Cyprus Limited. Tel: 8007 4433 (+356 99917558) malta_info@merck.com |
Deutschland MSD Sharp & Dohme GmbH Tel: 0800 673 673 673 (+49 (0) 89 4561 0) e-mail@msd.de | Nederland Merck Sharp & Dohme B.V. Tel: 0800 9999000 (+31 23 5153153) medicalinfo.nl@merck.com |
Eesti Merck Sharp & Dohme OÜ, Tel: +372.614.4200 msdeesti@merck.com | Norge MSD (Norge) AS Tlf: +47 32 20 73 00 msdnorge@msd.no |
Ελλáδα MSD Α.Φ.Β.Ε.Ε. Τηλ: +30 210 98 97 300 dpoc_greece@merck.com | Österreich Merck Sharp & Dohme Ges.m.b.H. Tel: +43 (0) 1 26 044 dpoc_austria@merck.com |
España Merck Sharp & Dohme de España, S.A. Tel: +34 91 321 06 00 msd_info@merck.com | Polska MSD Polska Sp. z o.o. Tel.: +48.22.549.51.00 msdpolska@merck.com |
France MSD France Tél: +33 (0)1 80 46 40 40 | Portugal Merck Sharp & Dohme, Lda Tel: +351 21 4465700 inform_pt@merck.com |
Hrvatska Merck Sharp & Dohme d.o.o. Tel: +385 1 66 11 333 croatia_info@merck.com | România Merck Sharp & Dohme Romania S.R.L Tel: + 4021 529 29 00 msdromania@merck.com |
Ireland Merck Sharp & Dohme Ireland (Human Health) Limited Tel: +353 (0)1 2998700 medinfo_ireland@merck.com | Slovenija Merck Sharp & Dohme, inovativna zdravila d.o.o. Tel: +386.1.520.4201 msd.slovenia@merck.com |
Ísland Vistor hf. Sími: + 354 535 7000 | Slovenská republika Merck Sharp & Dohme, s. r. o Tel: +421 2 58282010 dpoc_czechslovak@merck.com |
Italia MSD Italia S.r.l. Tel: 800 23 99 89 (+39 06 361911) medicalinformation.it@msd.com | Suomi/Finland MSD Finland Oy Puh/Tel: +358 (0)9 804 650 info@msd.fi |
Κ?προς Merck Sharp & Dohme Cyprus Limited Τηλ: 800 00 673 (+357 22866700) cyprus_info@merck.com | Sverige Merck Sharp & Dohme (Sweden) AB Tel: +46 77 5700488 medicinskinfo@merck.com |
Latvija SIA Merck Sharp & Dohme Latvija Tel: +371.67364.224 msd_lv@merck.com | United Kingdom (Northern Ireland) Merck Sharp & Dohme Ireland (Human Health) Limited Tel: +353 (0)1 2998700 medinfoNI@msd.com |
This leaflet was approved on
Detailed information on this medicine is available on the European Medicines Agency website: http://www.ema.europa.eu.
This information is intended for healthcare professionals only:
Instructions
A visual inspection of the vaccine should be performed to detect any foreign particles and/or unusual physical appearance of the contents before administration. The vial should be shaken well until a slightly opaque white suspension is obtained.